Huber, H.F.; Jaberi-Douraki, M.; DeVader, S.; Aparicio-Lopez, C.; Nava-Chavez, J.; Xu, X.; Millagaha Gedara, N.I.; Gaudreault, N.N.; Delong, R.K.
Targeting SARS-CoV-2 Variants with Nucleic Acid Therapeutic Nanoparticle Conjugates. Pharmaceuticals 2021, 14, 1012.
https://doi.org/10.3390/ph14101012
AMA Style
Huber HF, Jaberi-Douraki M, DeVader S, Aparicio-Lopez C, Nava-Chavez J, Xu X, Millagaha Gedara NI, Gaudreault NN, Delong RK.
Targeting SARS-CoV-2 Variants with Nucleic Acid Therapeutic Nanoparticle Conjugates. Pharmaceuticals. 2021; 14(10):1012.
https://doi.org/10.3390/ph14101012
Chicago/Turabian Style
Huber, Hanah F., Majid Jaberi-Douraki, Sarah DeVader, Cesar Aparicio-Lopez, Juliet Nava-Chavez, Xuan Xu, Nuwan Indika Millagaha Gedara, Natasha N. Gaudreault, and Robert K. Delong.
2021. "Targeting SARS-CoV-2 Variants with Nucleic Acid Therapeutic Nanoparticle Conjugates" Pharmaceuticals 14, no. 10: 1012.
https://doi.org/10.3390/ph14101012
APA Style
Huber, H. F., Jaberi-Douraki, M., DeVader, S., Aparicio-Lopez, C., Nava-Chavez, J., Xu, X., Millagaha Gedara, N. I., Gaudreault, N. N., & Delong, R. K.
(2021). Targeting SARS-CoV-2 Variants with Nucleic Acid Therapeutic Nanoparticle Conjugates. Pharmaceuticals, 14(10), 1012.
https://doi.org/10.3390/ph14101012